Salus Thomas D. 4

What Happened

• Thomas D. Salus, Chief Legal & Administration of Lifecore Biomedical, Inc. (LFCR), received a grant of 30,000 restricted stock units (RSUs) on 2026-03-02 (Transaction code A). The filing shows no per-share price (N/A) because this is an equity award rather than an open-market trade.

Key Details

• Transaction date: 2026-03-02 (Form 4 filed same day).
• Grant: 30,000 RSUs; price reported as N/A (award/grant).
• Conversion: RSUs convert to common stock on a 1-for-1 basis (Footnote F1).
• Vesting: RSUs vest on the 3rd anniversary of the grant date (Footnote F2).
• Shares owned after transaction: not disclosed in the filing.
• Filing timeliness: filed on the same date as the transaction (no late filing indicated).

Context

• RSUs are a compensation award, not an open-market purchase or sale; they typically vest over time and do not represent immediate buying or selling pressure. Because these RSUs vest three years from the grant date and convert 1:1 to common shares, any market impact would depend on future vesting and the insider’s actions at that time.